Painful diabetic neuropathy

Diabetic Medicine

Volumn 16, Issue 8, 1999, Pages 632-644

  Benbow, Susan J ^a,c   Cossins, L ^b   MacFarlane, I A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b Pain Research Institute   (United Kingdom)

^c HAIRMYRES HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Pain; Peripheral neuropathy; Tricyclic antidepressants

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; CAPSAICIN; LOCAL ANESTHETIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW;

DIABETIC NEUROPATHIES; HUMANS; NEURITIS; PAIN; PAIN MEASUREMENT;

EID: 0032705557     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00028.x     Document Type: Review

References (226)

1. Rollo J. Cases of Diabetes Melittus, 2nd edn. London: Dilly, 1798: 17-62.
2. Pavy FW. Address on diabetes. Washington International Congress. Medical News, Philadelphia, September 23, 1887: 357.
3. Boulton AJM, Ward JD. Diabetic neuropathies and pain. Clin Endocrinol Metab 1986; 15: 917-931.
4. Thomas PK. Painful diabetic neuropathy: mechanisms and treatment. Diabet Nutr Metab 1994; 7: 359-368.
5. Benbow S, Wallymahmed M, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med 1998; 91: 733-737.
6. Bowsher D. Neurogenic pain: diagnosis and treatment. Medical Times 1989; 117: 21-26.
7. Bowsher D. Pain pathways and mechanisms. In: Swerdlow M, Charlton E, eds. Relief of Intractable Pain, 4th edn. Amsterdam: Elsevier, 1989: 1-22.
8. Benbow SJ. The natural history, pathophysiology and treatment of diabetic neuropathy. MD Thesis, Bristol University, 1995.
9. Merskey H. Classification of chronic pain. Pain 1986; 3: 215-217.
10. Boulton AJM, Knight C, Drury J, Ward JD. The prevalence of symptomatic diabetic neuropathy in an insulin-treated population. Diabetes Care 1985; 8: 125-128.
11. Archer AG, Watkins PJ, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiat 1983; 46: 491-499.
12. Young KJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic neuropathy. Diabetes Care 1988; 11: 34-40.
13. Watkins PJ. Natural history of the diabetic neuropathies. Q J Med 1990; 77: 1209-1218.
14. Walters D, Gatling W, Mullee MA, Hill RD. The prevalence of diabetic distal sensory neuropathy in an English community. Diabetic Med 1992; 9: 349-353.
15. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
16. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. (The San Luis Valley Diabetes Study). Am J Epidemiol 1990; 131: 633-643.
17. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456-1461.
18. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EUROD1AB IDDM Complications study. Diabetologia 1996; 39: 1377-1384.
19. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 168-188.
20. Bruyn GW, Garland H. Neuropathies of endocrine origin. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam: North-Holland Publishing Company, 1970; 8: 29-71.
21. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 88-94.
22. Chan AW, MacFarlane IA, Bowsher DR, Wells JC, Bessex C, Griffiths K. Chronic pain in patients with diabetes mellitus; comparison with a non-diabetic population. The Pain Clinic 1990; 3: 147-159.
23. Bulpitt CJ, Shaw KM, Hodes C, Bloom A. The symptom pattern of treated diabetic patients. J Chron Dis 1976; 29: 571-583.
24. Boulton AJM, Scarpello JHB, Armstrong WD, Ward JD. The natural history of painful diabetic neuropathy - a 4 year study. Postgrad Med J 1983; 59: 556-559.
25. Mayne N. The short term prognosis of diabetic neuropathy. Diabetes 1968; 17: 270-273.
26. Benbow SJ, Chan AW, Bowsher D, MacFarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabetic Med 1994; 11: 17-21.
27. Bischoff A. The natural course of diabetic neuropathy: a follow up. Horm Metab Res 1981; 9: 98-100.
28. Fry IK, Hardwick C, Scott GW. Diabetic neuropathy: a survey and follow up of 66 cases. Guys' Hospital Reports 1962; 111: 113-129.
29. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabetic Med 1998; 15: 97-112.
30. Brown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy - a morphometric study. Arch Neurol 1976; 33: 164-171.
31. Young RJ, Zhou YQ, Rodriguez E, Prescott RJ, Ewing DJ, Clarke BF. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986; 35: 192-197.
32. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fibre degeneration and regeneration. Diabetes 1990; 39: 898-908.
33. Dyck PJ, Lambert EH, O'Brien PC. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976; 26: 466-471.
34. Llewelyn JG, Thomas PK, Fonseca V, King RHM, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol (Berl) 1986; 72: 157-163.
35. Kashiwamura H, Yagihashi S, Narita S, Baba M, Matsunaga M, Takebe K. Can the pain in diabetic neuropathy be accounted for by structural alterations. In Ward J, Goto Y, eds. Diabetic Neuropathy. Chichester: Wiley, 1990: 67-72.
36. Britland ST, Young RJ, Sharma AK, Clarke BF. Acute and remitting painful diabetic polyneuropathy: a comparison of peripheral nerve fibre pathology. Pain 1992; 48: 361-370.
37. Llewelyn JG, Gilbey SG, Thomas PK, King RHM, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy: a clinicopathological study. Brain 1991; 114: 867-892.
38. Said G, Goulon-Goeau C, Slama G, Tchobroutsky G. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus. N Engl J Med 1992; 326: 1257-1263.
39. Fowler JJ, Ochoa J. Unmyelinated fibres in normal and compressed peripheral nerves of the baboon: a quantitative electron microscopic study. Neuropath Appl Neurobiol 1975; i: 247-265.
40. Asbury AK, Fields HL. Pain due to peripheral nerve damage: an hypothesis. Neurology 1984; 34: 1587-1590.
41. Wall PD, Gutnick M. Properties of afferent nerve impulses originating from a neuroma. Nature 1974; 248: 740-743.
42. Scadding JW. Development of ongoing activity, mechanosensitivity and adrenaline sensitivity in severed peripheral nerve axons. Exp Neurol 1981; 73: 345-364.
43. Devor M. Nerve pathophysiology and mechanisms of pain in causalgia. J Autonom Nerv System 1983; 7: 371-384.
44. Granit R, Leksell L, Skoglund CR. Fibre interaction in injured or compressed regions of nerve. Brain 1944; 67: 125-140.
45. Granit R, Skoglund CR. Facilitation, inhibition and depression at the 'Artificial synapse' formed by the cut end of a mammalian nerve. J Physiol Lond 1945; 103: 435-448.
46. Seltzer Z, Devor M. Ephaptic transmission in chronically damaged peripheral nerves. Neurology 1979; 29: 1061-1064.
47. Meyer RA, Campbell JN. Coupling between unmyelinated peripheral nerve fibers does not involve sympathetic nerve efferents. Brain Res 1987; 437: 181-182.
48. Wall PD, Devor M. Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. Pain 1983; 17: 321-327.
49. Forman LJ, Estilow S, Lewis M, Vasilenko P. Streptozotocin alters immunoreactive beta-endorphin levels and pain perception after 8 weeks in female rats. Diabetes 1986; 35: 1309-1313.
50. Lee JH, Cox DJ, Mook DG, McCarty RC. Effects of hyperglycaemia on pain threshold in alloxan-diabetic rats. Pain 1990; 40: 105-107.
51. Morley GK, Mooradian AD, Levine AS, Moríey JE. Mechanism of pain in diabetic peripheral neuropathy. Am J Med 1984; 77: 79-82.
52. Chan AW, MacFarlane IA, Bowsher DR, Wells JCD. Does acute hyperglycaemia influence heat pain thresholds? J Neurol Neurosurg Psychiat 1988; 51: 688-690.
53. Chan AW, MacFarlane IA, Bowsher D. Short term fluctuations in blood glucose concentrations do not alter pain perception in diabetic patients with and without peripheral neuropathy. Diabetes Res 1990; 14: 15-19.
54. Boulton AJM, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982; 5: 386-390.
55. Boulton AJM. Causes of neuropathic pain. Diabetic Med 1993; 10 (Suppl. 2): 87S-88S.
56. Edmonds ME, Roberts VC, Watkins PJ. Blood flow in the diabetic neuropathic foot. Diabetologia 1982; 22: 9-15.
57. Archer AG, Roberts VC, Watkins PJ. Blood flow patterns in painful diabetic neuropathy. Diabetologia 1984; 27: 563-567.
58. Chan AW, MacFarlane IA, Bowsher DR. Contact thermography of painful diabetic neuropathic foot. Diabetes Care 1991; 14: 918-922.
59. Boulton AJM, Scarpello JHB, Ward JD. Venous oxygenation in the diabetic neuropathic foot: Evidence of arteriovenous shunting? Diabetologia 1982; 22: 6-8.
60. Boulton AJM, Hardisty CA, Worth RC, Drury J, Ward JD. Elevated glycosylated haemoglobin in diabetic neuropathy. Acta Diabet Lat 1982; XIX: 345-349.
61. Mathiesen ER, Hilsted J, Feldt-Rasmussen B, Bonde-Petersen F, Christensen NJ, Parving HH. The effect of metabolic control on haemodynamics in short term insulin-dependent diabetic patients. Diabetes 1985; 34: 1301-1305.
62. Fisher BM, Quin JD, Rumley A, Lennie M, Small M, McCuish AC et al. Effect of insulin-induced hypoglycaemia on haemostasis, fibrinolysis and haemorheology in insulin-dependent diabetic patients and control subjects. Clin Sci 1991; 80: 525-531.
63. Bowsher D. Neurogenic pain syndromes and their management. Brit Med Bull 1991; 47: 644-666.
64. Hannington-Kiff JG. Intravenous regional sympathetic block with guanethedine. Lancet 1974; i: 1019-1020.
65. Bonelli S, Conoscente F, Movilia PG, Restelli L, Francucci B, Gross E. Regional intravenous guanethedine versus stellate ganglion block in reflex sympathetic dystrophies. Pain 1983; 16: 297-307.
66. Shir Y, Seltzer Z. Effects of sympathectomy in a model of causalgiform pain produced by partial sciatic nerve injury in rats. Pain 1991; 45: 309-320.
67. Bennett GJ. The role of the sympathetic nervous system in painful peripheral neuropathy. Pain 1991; 45: 221-223.
68. Satoh J, Perl ER. Peripheral nerve injury causes cutaneous nociceptors to be excited by activation of catecholamine receptors. Soc Neurosci Abst 1990; 16: 1072.
69. Tsigos C, White A, Young RJ. Discrimination between painful and painless diabetic neuropathy based on testing of large somatic nerve and sympathetic nerve function. Diabetic Med 1992; 9: 359-365.
70. Tsigos C, Reed P, Weinkove C, White A, Young RJ. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care 1993; 16: 722-727.
71. Kopin IJ. Catecholamine metabolism and the biochemical assessment of sympathetic activity. Clin Endocrinol Met 1977; 6: 525-49.
72. Veves A, Manes C, Murray HJ, Young MJ, Boulton AJM. Painful neuropathy in diabetic patients with or without foot ulceration. Diabetes Care 1993; 16: 1187-1189.
73. Veves A, Young MJ, Manes C, Boulton AJM. Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy. Diabetes Care 1994; 17: 1200-1202.
74. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150: 971-978.
75. Said G. Progressive centripetal degeneration of axons in small fibre diabetic neuropathy. Brain 1983; 106: 791-807.
76. Ohnishi A, Dyck PJ. Loss of small peripheral neurons in Fabry disease: Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 1974; 31: 120-127.
77. Nathan PW. The gate-control theory of pain-A critical review. Brain 1976; 99: 123-158.
78. th World Congress on Pain. Amsterdam: Elsevier, 1988: 114-28.
79. Lombard MC, Larabi Y. Electrophysiological study of cervical dorsal horn cells in partially deafferented rats. Adv Pain Res Ther 1983; 5: 147-154.
80. Wynn-Parry CB. Pain in avulsion lesions of the brachial plexus. Pain 1980; 9: 41-53.
81. Chan AW, MacFarlane IA, Masson EA, Bowsher D, Morley JS, Venn RF. CSF enkephalins in diabetic neuropathy. Neuropeptides 1992; 22: 125-128.
82. Jensen TS. Mechanisms of Neuropathic Pain. In Campbell JN, ed. Pain 1996 - an Updated Review. Seattle: Internation Association for the Study of Pain, 1996: 77-86.
83. Hardy JD, Wolff HG, Goodell H. Pain Sensations and Reactions. Baltimore: Williams and Wilkins, 1952.
84. Hewer AJM, Keele CAA. A method of testing analgesics in man. Lancet 1948; ii: 683-688.
85. Lynn B, Perl ER. A comparison of four tests for assessing the pain sensitivity of different subjects and test areas. Pain 1977; 3: 353-365.
86. Murrin KR, Rosen M. Measurement of pain. In: Lipton S, Miles J, eds. Persistent Pain, Vol. 3. London: Academic Press, 1983: 17-38.
87. Margoles MS. The pain chart: special properties of pain. In Melzack R, ed. Pain Measurement and Assessment. New York: Raven Press, 1983: 215-225.
88. Scott J, Huskisson EC. Graphic representation of pain. Pain 1976; 2: 175-184.
89. Sriwatanakul K, Kelvie W, Lasagna L, Calimlin JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983; 34: 234-239.
90. Melzack R, Torgerson WS. On the language of pain. Anaesthesiology 1971; 34: 50-59.
91. Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975; 1: 277-299.
92. Masson EA, Hunt L, Gem JM, Boulton AJM. A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. Pain 1989; 38: 25-28.
93. Dyck PJ. Detection, characterisation, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32.
94. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997; 48: 332-338.
95. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
96. Samanta A, Burden AC. Rapid improvement in pain of diabetic neuropathy. Using an open-loop intravenous insulin infusion system. Practical Diabetes 1985; 2: 22-23.
97. Ziegler D, Dannehl K, Wiefels K, Gries FA. Differential effects of near-normoglycaemia for 4 years on somatic nerve dysfunction and heart rate variation in Type 1 diabetic patients. Diabetic Med 1992; 9: 622-629.
98. Bertelsman FW, Heimans JJ, Van Rooy JCGM, Dankmeijer HF, Visser SL, Van Der Veen EA. Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion. J Neurol Neurosurg Psychiat 1987; 50: 1337-1341.
99. Ward J, Armstrong W, Preston E, Best L, O'Malley B, Scarpello J. Pain in the diabetic leg: a trial of aspirin and dipyridamole in diabetic neuropathy. Pharmatherapeutica 1981; 2: 642-647.
100. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-1975.
101. Young RJ, Clarke BF. Pain relief in diabetic neuropathy: The effectiveness of imipramine and related drugs. Diabetic Med 1985; 2: 363-366.
102. Cohen KL, Harris S. Efficacy and safety of nonsteroidal antiinflammatory drugs in the therapy of diabetic neuropathy. Arch Intern Med 1987; 147: 1442-1444.
103. Lee R, Spencer PSJ. Antidepressants and pain: a review of the pharmacological data supporting the use of certain tricyclics in chronic pain. J Int Med Res 1977; 5: 146-156.
104. Gram LF. Antidepressants: receptors, pharmacokinetics and clinical effects. In Burrows GD, Norman T, Davies B, eds. Antidepressants. Amsterdam: Elsevier Science Publishers, 1983: 81-95.
105. Sindrup SH. Antidepressants in the treatment of diabetic neuropathy symptoms. Dan Med Bull 1994; 41: 66-78.
106. Dubner R, Bennett GJ. Spinal and trigeminal mechanisms of nociception. Ann Rev Neurosci 1983; 6: 381-418.
107. Sagen J, Proudfit HK. Evidence for pain modulation by pre- and postsynaptic noradrenergic receptors in the medulla oblongata. Brain Res 1985; 331: 285-293.
108. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990; 10: 262-270.
109. Biegon A, Samuel D. Interaction of tricyclic antidepressants with opiate receptors. Biochem Pharmacol 1980; 29: 460-462.
110. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980; 243: 1147-1150.
111. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-596.
112. Davis JL, Lewis SB, Gerich JE, Kaplan RA, Schultz TA, Wallin JD. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. JAMA 1977; 238: 2291-2292.
113. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251: 1727-1730.
114. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-144.
115. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
116. Sindrup SH, Gram LF, Skjold T, Froland A, Beck-Nielsen H. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47: 509-515.
117. Battla H, Silverblatt CW. Clinical trial of amitriptyline and fluphenazine in diabetic peripheral neuropathy. Southern Med J 1981; 74: 417-418.
118. Mitas JA, Mosley CA, Drager AM. Diabetic neuropathic pain: Control by amitriptyline and fluphenazine in renal insufficiency. Southern Med J 1983; 76: 462-463.
119. Khurana RC. Treatment of painful diabetic neuropathy with trazodone (letter). JAMA 1983; 250: 1392.
120. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151-153.
121. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brosen KX. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-255.
122. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.
123. Blackwell B. Side effects of antidepressant drugs. Psychiatry Update 1987; 6: 724-745.
124. Shader RI, Kennedy JS. Biological treatment. In Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, 5th edn. Baltimore: Williams & Wilkins, 1989: 2037-2049.
125. Sindrup SH, Skjold T, Grodum E, Brosen K, Gram LF, Beck-Nielsen H. Clomipramine versus desipramine versus placebo in the treatment of diabetic neuropathy symptoms. Br J Clin Pharmacol 1990; 30: 683-691.
126. Gomez-Perez FJ, Rull JA, Dies H, Rodrigues-Rivera G, Gonzales-Barranco J, Losanzo-Castaneda A. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985; 23: 395-400.
127. Roose SP, Glassman AH, Siris S, Walsh BT, Bruno RL, Wright LB. Comparison of imipramine and nortriptyline-induced orthostatic hypotension: a meaningful difference. J Clin Psychopharmacol 1981; 1: 316-319.
128. Mendel CM, Klein RF, Chappell DA, Dere WH, Gertz BJ, Karam JH et al. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA 1986; 255: 637-639.
129. Gade GN, Hofeldt FD,Treice GL. Diabetic neuropathic cachexia - beneficial response to combination therapy with amitriptyline and fluphenazine. JAMA 1980; 243: 1160-1161.
130. Gomez-Perez FJ, Choza R, Rios JM, Reza A, Huerta E, Aguilar CA et al. Nortriptyline-fluphenazine vs. carbamazepine in symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525-529.
131. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors. 1959-79. Arch Gen Psychiat 1982; 39: 473-481.
132. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aacs-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552.
133. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-227.
134. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: Double-blind cross-over trial. Diabetologia 1969; 5: 215-218.
135. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974; 48: 869-872.
136. Chakrabarti AK, Samantaray SK. Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine. Aust NZ J Med 1976; 6: 565-568.
137. Badran AM, Aly MA, Sous ES. A clinical trial of carbamazepine in the symptomatic treatment of diabetic peripheral neuropathy. J Egypt Med Assoc 1975; 58: 627-631.
138. Ellenberg M. Treatment of diabetic neuropathy with diphenylhydantoin. NY State J Med 1968; 68: 2653-2655.
139. Chadda VS, Mathur MS. Double-blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978; 26: 403-406.
140. Saudek CD, Werns MS, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 1977; 2: 196-199.
141. Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994; 28: 1188-1196.
142. Gabapentin Study Group no. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993; 43: 2292-2298.
143. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J 1995; 311: 1047-1052.
144. Boas RA, Covino BG, Shahnarian A. Analgesic responses to intravenous lignocaine. Br J Anaesth 1982; 54: 501-505.
145. Edwards WT, Habib F, Burney RG, Begin G. Intravenous lidocaine in the management of various chronic pain states. A review of 211 cases. Regional Anaesth 1985; 10: 1-6.
146. Kastrup J, Petersen P, Dejgaard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion - a new treatment of chronic painful diabetic neuropathy. Pain 1987; 28: 69-75.
147. Dejgaard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1988; i: 9-11.
148. Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15: 1550-1555.
149. Oskarsson P, Ljunggren JG, Lins PE, The Mexiletine Study Group. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. Diabetes Care 1997; 20: 1594-1597.
150. Wright JM, Oki JC, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacology 1997; 31: 29-34.
151. Buck SH, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 1986; 38: 179-226.
152. Lynn B. Capsaicin: actions on nociceptive C-fibres and therapeutic potential. Pain 1990; 41: 61-69.
153. Fitzgerald M. Capsaicin and sensory neurones - a review. Pain 1983; 15: 109-130.
154. Ross DR, Varipapa RJ. Treatment of painful diabetic neuropathy with topical capsaicin (letter). N Engl J Med 1989; 321: 474-475.
155. Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicentre, double-blind, vehicle controlled study. Arch Intern Med 1991; 151: 2225-2229.
156. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy (controlled study with long-term follow-up). Diabetes Care 1992; 15: 8-14.
157. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc 1991; 81: 288-293.
158. Chad DA, Aronin N, Lundstrom R, McKeon P, Ross D, Molitch M et al. Does capsaicin relieve the pain of diabetic neuropathy? (letter). Pain 1990; 42: 387-388.
159. Veves A, Boulton AJM. Measuring subjective symptoms (letter). Diabetes Care 1992; 15: 1434.
160. Capsaicin Study Group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992; 15: 159-165.
161. Zhang WY, Po ALW. The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharmacol 1994; 46: 517-522.
162. Biesbroek R, Bril V, Hollander P, Kabadi U, Schwartz S, Singh SP et al. A double-blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Adv Therapy 1995; 12: 111-120.
163. Levy DM, Abraham RR, Tomlinson DR. Topical capsaicin in the treatment of painful diabetic neuropathy (letter). N Engl J Med 1991; 324: 776-777.
164. Tandan R, Lewis GA, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy (Effect on sensory function). Diabetes Care 1992; 15: 15-18.
165. Ziegler D. Diagnosis and management of diabetic peripheral neuropathy. Diabetic Med 1996; 13: S34-S38.
166. Simpson BA. Spinal cord stimulation. Pain Rev 1994; 1: 199-230.
167. Kumar K, Toth C, Nath RK. Spinal cord stimulation for chronic pain in peripheral neuropathy. Surg Neurol 1996; 46: 363-369.
168. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1698-1701.
169. Benbow SJ, Watt J, Miles J, Tesfaye S, MacFarlane IA. Electrical spinal cord stimulation in painful diabetic neuropathy: long-term efficacy and safety. Diabetic Med 1998; 15 (Suppl. 1): S11.
170. Watkins ES, Koeze TH. Spinal cord stimulation and pain relief. Br Med J 1993; 307: 462.
171. Meyerson BA. Mechanisms of spinal cord stimulation as pain treatment. In Campbell JN, ed. Pain 1996 - an Updated Review. Seattle: Internation Association for the Study of Pain, 1996; 207-215.
172. Thorsteinsson G, Stonnington HH, Stillwell GK, Elveback LR. Transcutaneous electrical stimulation: a double-blind trial of its efficacy for pain. Arch Phys Med Rehabil 1977; 58: 8-13.
173. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20: 1702-1705.
174. Foster AVM, Eaton C, McConville DO, Edmonds ME. Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabetic Med 1994; 11: 768-772.
175. Greene DA, Lattimer SA. Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab Rev 1988; 4: 201-221.
176. Masson EA, Boulton AJM. Aldose redncrase inhibitors in the treatment of diabetic neuropathy. Drugs 1990; 39: 190-202.
177. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46: S82-S89.
178. Watkins PJ. Treatment for diabetic neuropathy. Diabetic Med 1996; 13: 1007-1008.
179. Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D et al. A mera-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. Diabetic Med 1996; 13: 1017-1026.
180. Tesfaye S, Price DE. Therapeutic approaches in diabetic neuropathy and neuropathic pain. In Boulton AJM, ed. Diabetic Neuropathy. Carnforth, Lancashire: Marius Press, 1997: 159-181.
181. Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic painful neuropathy. Diabetes 1983; 32: 938-942.
182. Boulton AJM, Levin S, Comstock J. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990; 33: 431-437.
183. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 1995; 49: 269-277.
184. Santiago JV, Sonksen PH, Bouhon AJM, Macleod A, Beg M, Bochenek W et al. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. J Diab Comp 1993; 7: 170-178.
185. Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y. Diabetic Neuropathy Study Group in Japan. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicentre study. J Diab Comp 1996; 10: 168-172.
186. Horrobin DF. The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukotr Essent Fatty Acids 1988; 31: 181-197.
187. Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies. Diabetic Med 1993; 10: 593-605.
188. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Med 1990; 7: 319-323.
189. Gamma-linolenic Acid Multicentre Trial Group. Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993; 16: 8-15.
190. Ledeen RW, Yu K, Rapport MM, Swanki K, eds. Ganglioside structure function and biomedical potential. Adv Exp Med Biol, Vol. 174. New York: Plenum Press, 1984.
191. Fedele D, Crepaldi G, Battistin L. Multicentre trial on gangliosides in diabetic peripheral neuropathy. Adv Exp Med Biol 1984; 174: 601-606.
192. Liniger C, Pernet A, Moody JF, Assal JPh. Effect of gangliosides on diabetic peripheral neuropathy. Diabetes Res Clin Pract 1989; 7: 251-258.
193. Lingetti M, Coto V, Rengo F, Sgamboto S, Innocenti A, Fiori MG. Gangliosides in the treatment of diabetic neuropathy: a randomised, double-blind, placebo-controlled, dose-finding study. Diab Nutr Metab 1992; 5: 275-282.
194. Horowitz SH. Ganglioside therapy in diabetic neuropathy. Muscle Nerve 1986; 9: 531-536.
195. Crepaldi G, Fedele D, Tiengo A, Battistin L, Negrin P, Pozza G et al. Ganglioside treatment in diabetic peripheral neuropathy: a multicentre trial. Acta Diabet Lat 1983; 20: 265-276.
196. Naarden A, Davidson J, Harris L, Moore J, DeFelice S. Treatment of painful diabetic polyneuropathy with mixed gangliosides. Adv Exp Med Biol 1984; 174: 581-592.
197. Hallen M, Flood T, Slater N, Dambrosia J. Trial of ganglioside therapy for diabetic neuropathy. Muscle Nerve 1987; 10: 822-825.
198. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991; 40; 873-877.
199. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. Diabetologia 1995; 38: 1425-1433.
200. Sachse G, Wilms B, Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. In Gries FA, Freund HJ, Rabe F, Berger H, eds. Aspects of Autonomic Neuropathy in Diabetes Horm Metab Res 1980; Suppl. series 9: 105-108.
201. Nelsen KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212-1218.
202. Tan Y-M, Croese J. Clonidine and diabetic patients with leg pains (Letter). Ann Intern Med 1986; 105: 633-634.
203. Ziegler D, Lynch SA, Muir J, Benjamin J, Max MB. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992; 48: 403-408.
204. Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'Enriched enrolment' design. Pain 1995; 60: 267-274.
205. Cohen KL, Lucibello FE, Chomiak MA. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care 1990; 13: 1074-1077.
206. Quatraro A, Minei A, De Rosa N, Giugliano D. Calcitonin in painful diabetic neuropathy (Letter). Lancet 1992; 339: 746-747.
207. Zieleniewski W. Calcitonin nasal spray for painful diabetic neuropathy (Letter). Lancet 1990; 336: 449.
208. Terrence CF, Fromm GH, Tenicela R. Baclofen as an analgesic in chronic peripheral nerve disease. Eur Neurol 1985; 24: 380-385.
209. Ide H, Fujiya S, Asanuma Y, Tsuji M, Sakai H, Agishi Y. Clinical usefulness of intrathecal injection of metliylcobalamin in patients with diabetic neuropathy. Clinical Therapeutics 1987; 9: 183-192.
210. Levin ER, Hanscom TA, Fisher M, Lauvstad WA, Lui A, Ryan A et al. The influence of pyridoxine in diabetic peripheral neuropathy. Diabetes Care 1981; 4: 606-609.
211. McCann VJ, Davis RE. Pyridoxine and diabetic neuropathy- a double-blind controlled study (letter). Diabetes Care 1983; 6: 102-103.
212. Quatraro A, Roca P, Donzella C, Acampora K, Marfella R, Giugliano D. Acetyl-L-carnitine for symptomatic diabetic neuropathy (Letter). Diabetologia 1995; 38: 123.
213. Hall DWR, Van Den Hoven WE. Influence of cyclandelate on in vitro red blood cell deformability. Drugs 1987; 33: 3-40.
214. Heimans JJ, Drukarch B, Matthaei I, Ijff GA, Bertelsmann FW, Strijers RLM et al. Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomised, cross-over study. Acta Neurol Scand 1991; 84: 483-486.
215. Cohen KL, Harris S. Pentoxifylline and diabetic neuropathy (Letter). Ann
216. Cohen SM, Matthews T. Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology 1991; 42: 741-746.
217. Shindo H, Tawata M, Aida K, Onaya T. Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neuropathy. Prostoglandins 1991; 41: 85-96.
218. Chan AW, Williams G, MacFarlane IA, Bowsher D. Octreotide, a long-acting somatostin analogue, in diabetic neuropathic pain (Letter). Horm Res 1991; 36: 86-87.
219. Wieman TJ, Patel VJ. Treatment of hyperesthetic neuropathic pain in diabetics. Ann Surgery 1995; 221: 660-665.
220. Armstrong DG, Fleischli JG, Lavery LA, Gilham KA. Is electrical stimulation effective in reducing neuropathic pain in patients with diabetes? Foot Ankle Surgery 1997; 36: 260-263.
221. Benbow SJ, Willimas G, MacFarlane IA. Smoking habits and painful diabetic neuropathy. J Diab Comp 1997; 11: 334-337.
222. Pfeifer MA, Ross DR, Schrage JP, Gelher DA, Schumer MP, Crain GM et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115.
223. Davies HTO, Crombie IK, Macrae WA. Why use a pain clinic? Management of neurogenic pain before and after referral. J Roy Soc Med 1994; 87: 382-385.
224. O'Keeffe ST. Restless leg syndrome - a review. Arch Int Med 1996; 156: 243-248.
225. Cavaliere D, Scorpiglione N, Belfiglio M, Carinci F, Cubasso D, Labbrozzi D et al. Quality assessment of randomised clinical trials on medical treatment of diabetic neuropathy. Diab Nutr Metab 1994; 7: 287-294.
226. Altman DG, Bland JM. Absence of evidence is not evidence of absence. Br Med J 1995; 311: 485.